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Abstract 14 
Carbohydrate (CHO) supplementation during prolonged exercise is widely acknowledged to 15 
blunt in vitro immunoendocrine responses but no study has investigated in vivo immunity.  16 
Purpose: To determine the effect of CHO supplementation during prolonged exercise on in 17 
vivo immune induction using experimental contact hypersensitivity (CHS) with the novel 18 
antigen Diphenylcyclopropenone (DPCP). 19 
Methods: In a double-blind design, 32 subjects were randomly assigned to 120 minutes of 20 
treadmill exercise at 60% ?̇?O2max with CHO (Ex-CHO) or placebo (Ex-PLA) 21 
supplementation. Responses were also compared to 16 resting control (CON) subjects from a 22 
previous study (for additional comparison with a resting non-exercise condition). 23 
Standardised diets (24 h pre-trial) and breakfasts (3.5 h pre-trial) were provided. Subjects 24 
received a primary DPCP exposure (sensitisation) 20 min after trial completion and exactly 25 
28 d later the strength of immune reactivity was quantified by magnitude of the cutaneous 26 
response (skin-fold thickness and erythema) to a low dose-series DPCP challenge. Stress 27 
hormones and leukocyte trafficking were also monitored.  28 
Results: CHO supplementation blunted the cortisol and leukocyte trafficking responses but 29 
there was no difference (P > 0.05) between Ex-CHO and Ex-PLA in the in vivo immune 30 
responses (e.g. both ~46% lower than CON for skin-fold response).   31 
Conclusions: CHO supplementation does not influence the decrease of in vivo immunity seen 32 
after prolonged exercise. The effects with more stressful (or fasted) exercise remain to be 33 
determined. However, there appears to be no benefit under the conditions of the present 34 
study, which have practical relevance to what many athletes do in training or competition.  35 
 36 
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integrated immune response 38 
 39 
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Introduction 40 
It is widely reported that athletes engaged in regular prolonged and/or strenuous exercise, and 41 
those in physically demanding occupations (e.g. soldiers), have a higher than normal 42 
incidence of upper respiratory tract illness (URTI) symptoms, which may be related to an 43 
exercise-induced impairment of immune function (immunodepression) [1, 2]. It has 44 
previously been suggested that the primary mechanisms contributing to such exercise-45 
induced immunodepression include the exercise-induced stress responses (i.e. increased 46 
stress hormones, in particular cortisol; cytokines; inflammatory responses); and the 47 
redistribution of leukocytes and their subsets (e.g. [3–5]).  Many nutritional interventions 48 
have been investigated as potential countermeasures to exercise-induced immunodepression 49 
and acute supplementation with carbohydrate (CHO) is often cited as the most efficacious [6–50 
8]. Supplementation with CHO has been consistently shown to blunt many of the exercise-51 
induced immune and endocrine perturbations (e.g. increased cortisol, cytokine, and leukocyte 52 
redistribution responses; decreased neutrophil degranulation and oxidative burst functions, 53 
lymphocyte proliferation and functions, natural killer cell function[4–12]) although it is not 54 
clear how this may influence infection risk [8, 12]. Such in vitro markers provide useful 55 
insight into the impact of nutritional interventions but alone they are considered to lack 56 
clinical relevance as the extent to which changes in these in vitro or ex vivo measures are 57 
related to increased infection risk is unclear [13, 14]. To date, the vast majority of the 58 
supportive evidence for CHO supplementation is based on in vitro measures (e.g. [4, 5, 9–59 
11]), with little evidence on URTI and no evidence on in vivo immunity. In one study, 60 
Nieman et al. [15] studied approximately 100 marathon runners randomly allocated to receive 61 
placebo or CHO beverages (providing ~60 g per hour) during a competitive marathon race. 62 
Carbohydrate supplementation was associated with higher post-race plasma glucose and 63 
insulin concentrations, and lower post-race cortisol and growth hormone concentrations. 64 
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However, they observed little benefit of CHO, compared to placebo, on the response of a 65 
range of salivary immune parameters (including IgA secretion rate, IgA relative to protein, 66 
and absolute IgA concentration, which actually decreased less in the placebo group). Nieman 67 
et al. [15] were also able to obtain URTI data for the 15-day post-race period from 93 of the 68 
participants, and found no difference in URTI incidence between the CHO and placebo 69 
groups. However, the validity of using self-reported URTI has been questioned [14].  70 
 71 
The normal immune response (and hence host defence and protection) involves a complex 72 
and co-ordinated network of molecules, cells and tissues working in synergy. Hence, in vivo 73 
immune markers are considered particularly valuable [13, 14]. Cutaneous measures of in vivo 74 
immunity, such as delayed type hypersensitivity responses to intradermal injection of 75 
antigens, or contact hypersensitivity (CHS) responses to epicutaneous application of antigens, 76 
represent challenge-type measures, which have recently been suggested to be most useful in 77 
immunonutrition studies, when considering biological relevance, sensitivity and feasibility 78 
[14]. The clinical relevance of examining cutaneous in vivo immunity is supported by studies 79 
that have used such measures to monitor immune-competence in HIV-infected patients [16], 80 
and studies showing that the magnitude of the responses relate to URTI risk in children [17] 81 
or predict mortality in patients with surgical infections [18]. It has been previously 82 
demonstrated that the CHS response, using the novel antigen diphenylcyclopropenone 83 
(DPCP), is significantly reduced after 2 hours of treadmill running. This includes both the 84 
induction of immunity (-53%), in participants with no prior exposure, and the elicitation of 85 
immunity (-19%), in participants with well-established immune memory, to DPCP [19]. We 86 
have now demonstrated this as a controllable, reproducible, sensitive, and valid in vivo 87 
marker of exercise-induced immunodepression [19, 20]. Furthermore, we have recently 88 
demonstrated no effect of the same exercise (2 h of treadmill running) on the skin’s response 89 
5 
 
to the irritant croton oil [20], providing further support for the suggestion that the observed 90 
decrease in in vivo immune induction to DPCP is an antigen-specific, T cell mediated, 91 
response.  92 
  93 
Challenging the skin using novel antigens permits the investigation of the influence of 94 
stressors on in vivo immune induction and allows rigorous control of both the dose and 95 
timing of sensitisation [19]. We are not aware of any previous study that has utilised such an 96 
in vivo marker to determine the effects of nutritional interventions such as CHO 97 
supplementation on exercise-induced immunodepression. To date, the most supportive 98 
evidence for a nutritional strategy to limit the exercise-induced immune perturbations is for 99 
CHO supplementation, but no study has investigated in vivo immunity. Therefore, the aim of 100 
the present study was to determine the effects of acute CHO ingestion, before, during and 101 
after prolonged exercise, on induction of the CHS response to DPCP.  We hypothesised that 102 
CHO supplementation would blunt the prolonged exercise-induced decrease of CHS 103 
induction.  104 
 105 
Experimental Methods 106 
This study was conducted according to the guidelines laid down in the Declaration of 107 
Helsinki (2008, including 2013 amendments) and all procedures were approved by the local 108 
University Research Ethics Committee. Written informed consent was obtained from all 109 
subjects. Subjects also completed a pre-exercise screening questionnaire (Physical Activity 110 
Readiness Questionnaire: PAR-Q) before participating in each exercise test. 111 
 112 
Subjects  113 
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Thirty two men were included in this study (age 28.8 ± 8.1 years, body mass 76.2 ± 10.1 kg, 114 
maximal oxygen uptake, ?̇?O2max, 58.3 ± 6.4 mL.min-1.kg-1; means ± standard deviation for 115 
all 32 subjects; values for individual groups are summarised in Table 1). All participants were 116 
healthy, non-smoking, and recreationally active (familiar with running) with no previous 117 
history of exposure to DPCP. Subjects were excluded if they were taking any medication or 118 
dietary supplements, had a history of atopy or any other immune-related or inflammatory 119 
dermatological or relevant medical conditions. Other exclusion criteria included current (or 120 
within two weeks of recovery from) an infection prior to the study, having any vaccinations 121 
in the 2 months preceding the study, and donating blood in the four weeks before the study.   122 
Participants were asked to abstain from strenuous exercise in the 24 hours before and 48 123 
hours following each trial (exercise/sensitisation and elicitations).  Participants were asked to 124 
abstain from the consumption of alcohol or caffeinated drinks 48 hours ahead of each trial.  125 
 126 
Study design 127 
In the current study, 32 subjects were randomly assigned to either 120 minutes of treadmill 128 
exercise at 60% ?̇?O2max with CHO supplementation (Ex-CHO, n = 16), or 120 minutes of 129 
treadmill exercise at 60% ?̇?O2max with placebo (Ex-PLA, n = 16). As a point of reference 130 
for the normal response in rested individuals, we also statistically compared the Ex-CHO and 131 
Ex-PLA groups’ in vivo immune induction responses to the control group (CON, n = 16, who 132 
completed 120 minutes of seated rest) from Diment et al. [20]. Subjects were allocated 133 
randomly into either the Ex-CHO or Ex-PLA groups after being matched for physical 134 
characteristics, speed at gas exchange threshold (GET) and speed at ?̇?O2max (and hence 135 
relative exercise intensity in the main trials). The PLA and CHO conditions were 136 
administered in a double-blind manner. All subjects undertook two preliminary tests 137 
(?̇?O2max determination and familiarisation) and one main trial.    138 
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 139 
Determination of maximal oxygen uptake (?̇?O2max) 140 
?̇?O2max was determined by an incremental exercise test on a motorised treadmill 141 
(H/P/Cosmos Sport and Medical, Nussdorf-Traunstein, Germany) in accordance with the 142 
methods of Diment et al. [20].  The test began at a treadmill speed of 5 km·h-1, with a 1% 143 
incline, for 3 minutes.  The speed was then increased by 1 km·h-1 every minute until a speed 144 
of 18 km·h-1 was attained and then further increases were achieved by increasing the gradient 145 
by 1% every minute until volitional exhaustion.  Heart rate was recorded throughout using a 146 
short range telemetry heart rate monitor (Polar 810i, Polar Electro, Kempele, Finland); rating 147 
of perceived exertion (RPE) was recorded at the end of each minute [21]; breath-by-breath 148 
gas exchange was recorded using an online system (Cortex Metalyser 3B, Cortex Biophysik, 149 
GmbH, Leipzig, Germany) throughout the duration of the test.  The gas analysis system was 150 
calibrated prior to use according to the manufacturer's guidelines using a calibration gas of 151 
known composition and a three-litre syringe (Hans Rudolf Inc, Kansas, USA). ?̇?O2max was 152 
recorded as the highest average ?̇?O2 over any 30 second period of the test. The speed required 153 
to elicit 60% ?̇?O2max was estimated from the linear part of the ?̇?O2 - speed relationship, and 154 
later verified in the familiarisation trial. The intensity at 60% ?̇?O2max was also expressed as a 155 
percentage of the difference between GET and ?̇?O2max (%Δ) in accordance with the 156 
methods of Lansley et al. [19], to verify that the relative intensity (and hence relative 157 
physiological stress) were equal between exercise groups. 158 
 159 
Familiarisation  160 
Subjects completed a familiarisation session one week prior to the main trial.  Participants 161 
completed a warm-up for 5 minutes at 5 km·h-1 and 1% gradient on the same treadmill used 162 
for the ?̇?O2max test. This was immediately followed by a 60 minute run at a speed equivalent 163 
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to 60% ?̇?O2max to familiarise subjects to the main trial exercise procedures and confirm 164 
accuracy of the calculated speed (to elicit 60% ?̇?O2max). Minor speed adjustments were made 165 
during the first 15 min if necessary to attain the target 60% ?̇?O2max. Subjects were provided 166 
with 5 ml·kg-1 body mass water bolus 20 min before exercise commencement and on trial 167 
completion and 2 ml·kg-1 was provided every 15 min during the trial to familiarise subjects 168 
with the fluid provision schedule to be followed in the main trials. Heart rate and RPE were 169 
recorded every 5 min.  170 
 171 
Main trials 172 
Standardisation and pre-exercise preparation of subjects: Dietary intake was controlled 173 
during the 24 h before the main experimental trial by providing subjects with 35 mL·kg-1·d-1 174 
water and food from a standard food list to meet their estimated daily energy requirement 175 
(11.4 ± 1.5 MJ·d-1, which was comprised of 15%, 60%, and 25% of energy from protein, 176 
CHO and fat respectively, and was equivalent to ~1.3, 5.4 and 1.0 g·kg-1 body mass, 177 
respectively). They were also provided with a standard breakfast at 07:30 on the morning of 178 
the main trial to provide ~0.03 MJ·kg-1 (equivalent to 2.4 ± 0.3 MJ, comprised of ~0.2, 1.0 179 
and 0.2 g·kg-1 of protein, CHO and fat, respectively). To further standardise dietary intake 180 
subjects were also provided with lunch after the final blood sample collection (see timings 181 
below), to provide ~0.02 MJ·kg-1 (equivalent to 1.6 ± 0.2 MJ, comprised of ~0.2, 1.0 and 0.2 182 
g·kg-1 of protein, CHO and fat, respectively).  183 
 184 
Experimental procedures  185 
Subjects were provided with breakfast (as detailed above) at 07:30 before beginning the 120 186 
min exercise (Ex-CHO and Ex-PLA) at 11:00. They were also provided with a quantity of 187 
water for the 3 h period between 07:30 and 10:30 proportional to their daily requirement but 188 
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pro rata for this period (based on their calculated requirement for the prior 24 h, equating to 189 
approximately 6.6 mL·kg-1). During this period they were required to be restful but were 190 
allowed to undertake light activities such as reading or using a computer. They were then 191 
required to sit for 10 min with minimal movement before resting blood samples were 192 
collected. Subjects received a bolus of 5 mL·kg-1 of their respective drink (CHO or PLA) 20 193 
min before and immediately after exercise and 2 mL·kg-1 every 15 min during exercise. 194 
Exercise commenced at 11:00 and immediately after the trial, post-exercise blood samples 195 
were collected, then subjects showered and returned to the laboratory within 15 minutes of 196 
completion for patch application at exactly 20 min post-exercise (i.e. 13:20) to sensitise 197 
subjects to DPCP (details below). A final blood sample was also obtained 1 h post-exercise. 198 
During exercise, expired gas was analysed during minutes 10, 20, 40, 50, 70, 80, 100, and 199 
110 of exercise using the Douglas bag method. Gas was analysed using a gas analyser 200 
(Servomex, Crowborough, UK) and a dry gas meter (Harvard Apparatus, Edenbridge, UK).  201 
The gas analyser was calibrated prior to use according to the manufacturer’s guidelines using 202 
calibration gasses of known composition. Heart rate and RPE were recorded every 15 min 203 
during exercise. Elicitation was then performed (details below) exactly 28 days after this trial.  204 
 205 
Drink composition: The CHO drink was prepared with a lemon flavoured CHO-based sports 206 
drink powder (Go Energy, Science in Sport, Nelson, UK) according the manufacturer’s 207 
instructions (to give a CHO concentration of 10% w/v). The placebo was CHO-free and 208 
prepared from sugar-free, artificially sweetened lemon flavoured drink concentrate (Tesco, 209 
Dundee, UK) diluted 4 parts water to 1 part concentrate. The concentrations were determined 210 
so that drinks were taste matched as closely as possible. Even though this may not be 211 
necessary with the between groups design employed here, we taste matched drinks as closely 212 
as possible to avoid potential loss of blinding (i.e. subjects discussing their drinks outside of 213 
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the study/laboratory). A laboratory technician, independent of the study, was responsible for 214 
the drink preparation to maintain double-blind procedures. The drinking schedule provided 215 
approximately 60 g CHO per hour during exercise (in addition to the pre- and post-exercise 216 
boluses of ~40 g each) for an average sized subject.   217 
 218 
Induction of contact sensitivity (sensitisation) 219 
Subjects were sensitized to DPCP at 13:20, exactly 20 min post-exercise (to ensure cutaneous 220 
blood flow had returned to baseline) in accordance with the methods of Harper Smith et al. 221 
[19] and Diment et al. [20]. Sensitisation was achieved by the application of an occluded 222 
patch, constituting a 12 mm aluminium Finn chamber (Epitest Oy, Tuusula, Finland) on 223 
scanpor hypoallergenic tape containing an 11 mm filter paper disc. The disc was soaked in 224 
22.8 μl of 0.125 % DPCP in acetone and allowed to dry for 5 minutes before being applied to 225 
the skin on the lower back, for exactly 48 h. This provides a dose of 30 μg∙cm-2 DPCP on the 226 
patch.  227 
 228 
Elicitation 229 
The magnitude of in vivo immune responsiveness was quantified by measuring the responses 230 
elicited by secondary exposure to the same antigen, also in accordance with the methods of 231 
Harper Smith et al. [19] and Diment et al. [20]. Exactly 28 days after the initial sensitisation 232 
to DPCP, all subjects received a challenge with a low concentration dose-series of DPCP on 233 
individual patches, each comprising an 8 mm aluminium Finn chamber on scanpor 234 
hypoallergenic tape containing a 7 mm filter paper disc. Patches were applied to the inner 235 
aspect of the upper arm in the following doses of DPCP per patch: 1.24 μg∙cm-2; 1.98 μg∙cm-236 
2; 3.17 μg∙cm-2; 5.08 μg∙cm-2; 8.12 μg∙cm-2 and an additional acetone only control patch for 237 
background subtraction. Patches were applied in randomly allocated order at the local site in 238 
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order to minimize any anatomical variability in responses. This pattern was matched between 239 
subjects in each of the groups however (i.e. for every allocation pattern used in one group 240 
there was an equivalent identical pattern used in the other). Elicitation patches were removed 241 
after precisely 6 h and the strength of immune reactivity was assessed as cutaneous responses 242 
at 48 h post-application.  This method allows the magnitude of in vivo immune 243 
responsiveness to be quantified (e.g. establishment of immune memory) following 244 
sensitisation during the post-exercise period.  245 
 246 
Assessment of cutaneous responses  247 
Skin oedema (inflammatory swelling) is considered the key measure of CHS elicitation 248 
responses [19]. This was assessed as mean skin-fold thickness from triplicate measurements 249 
at each elicitation site using modified spring-loaded skin callipers (Harpenden Skin-fold 250 
Calliper, British Indicators, England), to the nearest 0.1 mm (measuring skin-fold only: i.e. 251 
no subcutaneous fat) as described previously [19, 20]. Skin erythema was determined from 252 
triplicate measurement at each patch site using an erythema meter (ColorMeter DSM11, 253 
Cortex Technology, Hadsund, Denmark) as previously described [19, 20]. Mean background 254 
values were determined from triplicate measurements at the acetone only control patch site 255 
for thickness and erythema. In order to determine the increase in thickness and erythema in 256 
response to DPCP, the value from the acetone only control site was subtracted from each 257 
patch site value. The values for increase in skin-fold thickness, and erythema over all the 258 
doses were summed to give a representative measure of the overall reactivity of each subject 259 
to DPCP [19, 20]. The dose-response curve was also used to conduct sensitivity analyses (i.e. 260 
identify the minimal dose required to elicit a positive response, for the skin-fold measure) in 261 
accordance with the methods of Harper Smith et al. [19].  262 
 263 
12 
 
Blood samples 264 
Blood samples were obtained by venepuncture, with minimal stasis, from an antecubital vein 265 
and collected into vacutainer (Becton Dickinson, Oxford, UK) tubes (containing lithium 266 
heparin or K3EDTA). All blood samples were obtained while subjects were in the seated 267 
position. Subjects were asked to sit without changes of posture and minimal movement for 10 268 
min before all blood samples were drawn, except the Post-Ex sample, which was drawn as 269 
soon as possible after completing the exercise (within 5 min). A small aliquot was taken from 270 
the K3EDTA tube for haematological analysis and then all samples were centrifuged 271 
immediately at 1500 × g for 10 minutes at 4°C.  Aliquots of plasma were stored -80°C for 272 
later analysis.   273 
 274 
Analytical methods 275 
Haematological analysis was performed on the K3EDTA treated blood aliquot using 276 
automated haematology analysers (Gen-S, Beckman Coulter, High Wycombe, UK; ABX 277 
Pentra 60C+, Horiba Medical, France).   278 
 279 
*** Please insert table 1 near here *** 280 
 281 
Glucose concentration was determined in heparinised plasma using an automated analyser 282 
(YSI 2300 Stat Plus, Yellow Springs, OH, USA).  Plasma cortisol concentration in 283 
heparinised plasma was determined using a commercially available enzyme linked 284 
immunosorbent assay (ELISA) kit (DRG, Germany; Biomercia, Ca, USA). Plasma 285 
epinephrine and norepinephrine concentrations in K3EDTA plasma were determined using a 286 
commercially available CatCombi ELISA (IBL International, Hamburg, Germany). All 287 
plasma samples were thawed only once prior to analysis. 288 
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 289 
Data analysis 290 
Statistical analyses were carried out using SPSS (IBM SPSS Statistics for Windows, Version 291 
21.0, Armonk, NY: IBM Corp.). Values were compared between groups using 1-way 292 
independent ANOVA or, for variables with repeated measures, 2-way mixed ANOVA. If 293 
data were not normally distributed they were first normalised with log transformation using 294 
the natural log (training hours, %Δ @ 60% ?̇?O2max, neutrophil count, neutrophil-to-295 
lymphocyte ratio, adrenaline, noradrenaline summed skin-fold responses), or 1/x2 (total 296 
leukocyte count) transformations. Post hoc Holm-Bonferroni corrected paired (for within 297 
groups comparisons) or independent (for between groups) t-tests were applied where 298 
appropriate. All results are presented as mean  standard deviation unless otherwise stated. 299 
 300 
Results 301 
Participants were well matched for physical characteristics with no significant differences for 302 
any of the physical parameters except ?̇?O2max, (Table 1). However, exercise responses were 303 
similar between groups (Table 2) and, importantly, there was no difference in the trial relative 304 
exercise intensity (this holds true whether expressing relative intensity as % ?̇?O2max during 305 
the trial or %Δ, whereby exercise intensity is expressed relative to the individual GET and 306 
?̇?O2max).  307 
 308 
*** Please insert Table 2 near here *** 309 
 310 
CHS responses to DPCP 311 
Oedema responses: For the skin-fold responses, 1-way independent ANOVA (including 312 
comparison to the CON group from [20]) showed a main effect of group (F2,45 = 3.370, P = 313 
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0.043). There was no difference between the Ex-CHO or Ex-PLA groups (post hoc analysis: 314 
between Ex-PLA and Ex-CHO, P = 0.460; mean difference 1.04 mm, 95% confidence 315 
intervals 0.45 to 2.41 mm) but there was a difference between the CON and Ex-PLA (P = 316 
0.026, mean difference 2.29 mm, 95% confidence intervals 1.11 to 4.71 mm) and between 317 
CON and Ex-CHO (P = 0.036, mean difference 2.38 mm, 95% confidence intervals 1.13 to 318 
5.02 mm, see Figure 1). The exercise trials were both ~46% lower (P < 0.05) than the CON 319 
responses reported by Diment et al. [20]. Sensitivity analysis revealed the average threshold 320 
dose for a response to DPCP was 0.45 μg·cm2 for the CON group but a dose ~3-fold higher 321 
was required (2.81-fold for PLA and 2.88-fold for CHO, see Figure 1) in order to elicit a 322 
positive response in the exercise groups. 323 
 324 
*** Please insert Figure 1 near here *** 325 
 326 
Erythema responses: One-way independent ANOVA (including comparison to the CON 327 
group from [20]) showed a main effect of group (F2,45 = 3.219, P = 0.049). There was no 328 
difference between the Ex-CHO or Ex-PLA groups (post hoc analysis: between Ex-PLA and 329 
Ex-CHO, P = 0.290, mean difference 4.22 AU, 95% confidence intervals -11.16 to 19.60 AU; 330 
between CON and Ex-PLA, P = 0.070, mean difference 14.29 AU, 95% confidence intervals 331 
-1.25 to 29.83 AU; between CON and Ex-CHO, P = 0.036, mean difference 18.51 AU, 95% 332 
confidence intervals 2.6 to 34.41 AU, see Figure 2).  333 
 334 
*** Please insert Figure 2 near here *** 335 
 336 
Blood leukocyte counts 337 
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It was not possible to obtain a blood sample at every time point for some individuals (for 338 
example, if a post-exercise sample could not be obtained within 5 min it was abandoned to 339 
avoid delays in patch application, as the CHS responses were of primary importance). For 340 
this reason the sample sizes for these measures were n = 12 for the Ex-PLA group and n = 11 341 
for the Ex-CHO group. Significant main effects for ANOVA comparisons (group, time and 342 
group × time) were evident for most leukocyte parameters (total leukocyte count, neutrophil 343 
count, lymphocyte count, and neutrophil-to-lymphocyte ratio) with the exception of no 344 
significant group effects for total leukocyte count, lymphocyte count, and neutrophil-to-345 
lymphocyte ratio (detailed in Table 3). Post hoc analysis on the time effect (in each group 346 
separately, owing to the observed interactions) showed that significant leukocyte trafficking 347 
was evident in Ex-PLA at Post-Ex (P < 0.001) and 1 h Post-Ex (P < 0.001) and Ex-CHO at 348 
Post-Ex (P = 0.002) and 1 h Post-Ex (P < 0.001) but counts were significantly lower at both 349 
post-exercise (P = ???) and 1 h Post-Ex (P = ???) times in the Ex-CHO compared to Ex-PLA 350 
group (see Table 3). Significant neutrophil trafficking was evident in Ex-PLA at Post-Ex (P < 351 
0.001) and 1 h Post-Ex (P < 0.001) and Ex-CHO at Post-Ex (P < 0.001) and 1 h Post-Ex (P = 352 
0.004) but counts were significantly lower at both post-exercise (P = ???) and 1 h Post-Ex (P 353 
= ???) times in the Ex-CHO compared to Ex-PLA group (see Table 3). A significant time 354 
effect was evident for lymphocyte count (trafficking) and a significant group × time 355 
interaction indicates that this pattern differs between groups. Post hoc comparison did not 356 
reveal any between group differences at any of the time points (Table 3) but there was a 357 
significant increase in Ex-PLA at Post-Ex (P = 0.006) but no change over time in the Ex-358 
CHO group (P = 0.262). The neutrophil-to-lymphocyte ratio increased significantly in Ex-359 
PLA at Post-Ex (P < 0.001) and 1 h Post-Ex (P < 0.001) and Ex-CHO at Post-Ex (P = 0.028) 360 
and 1 h Post-Ex (P = 0.020) but neutrophil-to-lymphocyte was significantly lower at 1 h Post-361 
Ex in the Ex-CHO compared to Ex-PLA group (see Table 3).  362 
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 363 
*** Please insert Table 3 near here *** 364 
 365 
Stress hormones and glucose 366 
For stress hormones and glucose n = 12 for the Ex-PLA group and n = 11 for the Ex-CHO 367 
group. Significant main effects of group, time and group × time interaction were evident for 368 
plasma glucose, which was significantly higher at post-exercise and 1 h post-exercise in the 369 
Ex-CHO group compared to Ex-PLA (Table 4). Post hoc analysis on the time effect (in each 370 
group separately, owing to the observed interaction) revealed a significant decrease below 371 
Pre-Ex concentration at 1 h Post-Ex in the Ex-PLA group (P = 0.032) and a significant 372 
increase at Post-Ex (P < 0.001) and 1 h Post-Ex (P = 0.011) in the Ex-CHO group.  373 
 374 
Significant main effects of time, and group × time interaction were evident for plasma 375 
cortisol, which was significantly lower post-exercise and 1 h post-exercise in the Ex-CHO 376 
compared to the Ex-PLA group (Table 4). Post hoc analysis on the time effect (in each group 377 
separately, owing to the observed interaction) revealed no differences in the Ex-PLA group 378 
(P > 0.05) and a significant decrease at Post-Ex (P < 0.001) and 1 h Post-Ex (P < 0.001) in 379 
the Ex-CHO group (in line with the normal expected diurnal pattern). 380 
 381 
Significant main effects of time were evident for both adrenaline and noradrenaline (i.e. an 382 
exercise response) but there were no differences between Ex-CHO and Ex-PLA groups 383 
(interactions P > 0.05, Table 4). Post hoc analysis on the time effect (both groups considered 384 
together, owing to the lack of interaction) revealed a significant increase in plasma adrenaline 385 
concentration (P = 0.013) and noradrenaline concentration (P < 0.001) at Post-Ex.   386 
  387 
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*** Please insert table 4 near here *** 388 
 389 
Discussion 390 
The aim of the present study was to determine the effects of acute CHO ingestion, before, 391 
during, and after prolonged exercise, on the in vivo immune response (CHS) to the novel 392 
contact antigen DPCP.  The main findings were that despite CHO ingestion blunting the 393 
cortisol and leukocyte trafficking responses to prolonged treadmill running, there was no 394 
effect on in vivo immune response to DPCP. When comparing to the resting CON group from 395 
Diment et al. [20] in vivo immune induction (oedema assessed by skin-fold thickness) in the 396 
present study was significantly lower (-46%). Sensitivity analysis also revealed that the 397 
threshold dose for a response to DPCP was ~3-fold higher (2.81-fold for PLA and 2.88-fold 398 
for CHO) in order to elicit a positive response. Previous research has consistently 399 
demonstrated that prolonged exercise (2 h treadmill running at 60% ?̇?O2max) reduces in vivo 400 
immune induction as assessed by this method [19, 20]. The exercise groups in the present 401 
study exhibited similar responses to the exercise groups in both of these previous studies [19, 402 
20]. This, in conjunction with direct statistical comparison with the CON group of Diment et 403 
al. [20], shows that the prolonged exercise in the present study reduced in vivo immune 404 
induction. However, the present study suggests that this decrease is not altered by acute CHO 405 
supplementation.  406 
 407 
Challenging the skin using novel antigens permits the investigation of the influence of 408 
stressors on in vivo immune induction and allows rigorous control of both the dose and 409 
timing of sensitisation [19]. However, we are not aware of any previous study that has 410 
utilised in vivo immune induction of CHS to determine the effects of nutritional interventions 411 
on exercise-induced immunodepression. Despite the large body of research showing CHO 412 
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supplementation to blunt the prolonged exercise-induced responses for a wide array of 413 
immune markers (e.g. [4, 5, 9–11]), there is a lack of evidence on the effects of CHO 414 
supplementation on in vivo immune function and/or clinically relevant outcomes. The 415 
findings of the present study, that CHO supplementation did not benefit in vivo immunity 416 
post-exercise, is broadly in line with Nieman et al. [15] who compared placebo or CHO 417 
beverage-supplemented runners during a competitive marathon race. In that study Nieman et 418 
al. [15] observed CHO supplementation (approximately 60 g per hour) to be associated with 419 
higher post-race plasma glucose and insulin concentrations, and lower post-race cortisol and 420 
growth hormone concentrations. However, there was no difference between the CHO and 421 
placebo groups in salivary IgA responses (considered high value markers in relation to URTI 422 
risk, [14]) or URTI incidence in the 15-day post-race period.  However, as this was a field-423 
based study in which subjects were racing, it is possible that performance would have 424 
differed (relative to each individual’s current potential performance or fitness) or that the 425 
CHO could have ergogenic effects meaning it is difficult to confirm whether subjects were 426 
exposed to the same relative stress (both physiological and psychological) in each group. 427 
Hence, in the present study we investigated in vivo immune function using the CHS 428 
‘challenge-test’ with otherwise standardised diet and exercise conditions. Given the outcomes 429 
previously reported for immune markers, with CHO supplementation, we hypothesised that 430 
CHO would protect against the exercise-induced decrease of in vivo immunity. However, 431 
contrary to our original hypothesis, and despite significant blunting of the leukocyte (and 432 
leukocyte subset) trafficking and cortisol responses, there was no difference between the Ex-433 
CHO and Ex-PLA groups in in vivo immune function. Therefore, these results suggest that 434 
CHO supplementation does not protect against prolonged exercise-induced 435 
immunodepression when assessed using an in vivo immune marker, which we [19, 20] and 436 
others [14] propose to be of clinical relevance in an exercise immunology context.  437 
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 438 
For consistency between groups, we were careful to control diet and CHO intake before (i.e. 439 
on the day before and the morning of) the main trials and during the period of sensitisation so 440 
that the only difference between groups was CHO content of drinks consumed acutely before, 441 
during, and after the prolonged exercise. Many previous studies required subjects to exercise 442 
following an overnight fast and it is possible, therefore, that immune alterations would be 443 
more pronounced in these circumstances. We chose to provide a standard breakfast in order 444 
to replicate what many athletes often do in training and competition and, as such, our results 445 
have practical relevance to such athletes. This presents the possibility that CHO 446 
supplementation during exercise would be more beneficial if exercise was commenced in the 447 
fasted state, which may be used by some athletes in certain sessions (e.g. see reference [20] 448 
for a recent review on the practice of training with low CHO availability). However, 449 
consuming a CHO-containing beverage would be counterproductive to any athlete wishing to 450 
practice this ‘train low’ method (as it would negate the fundamental principle of training 451 
low). As such, our approach for determining the effect of acute CHO ingestion on the in vivo 452 
immune responses to prolonged exercise in the fed state seems the most valid and of practical 453 
relevance for athletes. In the current study, the fact that we still observed notable differences, 454 
between the Ex-CHO and Ex-PLA conditions, in plasma glucose, leukocytosis and a number 455 
of stress markers typically associated with exercise and/or CHO ingestion demonstrates that 456 
there was a meaningful difference between the Ex-CHO and Ex-PLA groups in terms of the 457 
stress response to exercise. We suggest, therefore, that the lack of difference between CHO 458 
and PLA conditions in the present study cannot be explained by the fact that subjects were 459 
fed a standard breakfast 3.5 h before the exercise trials. These findings are in line with 460 
previous studies showing that in vivo immune responses to DPCP are unrelated to stress 461 
hormone responses induced by exercise [20] or altitude [21]. Taken together, this offers a 462 
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feasible explanation for the lack of effect of CHO supplementation on DPCP responses, 463 
despite a blunting of many of the stress response markers typically proposed to be responsible 464 
for the immunodepressive effects associated with prolonged and strenous exercise.  Induction 465 
of CHS is dependent upon dendritic cell activation at the skin, dendritic cell migration from 466 
the skin to the regional lymph nodes and subsequent clonal expansion of specific T cells [22], 467 
and represents an in vivo measure of the whole integrated immune response. As we have 468 
demonstrated no effect of CHO supplementaiton on this in vivo immune measure, and since 469 
the stress hormone (particularly cortisol) response does not seem to be implicated [20], it is 470 
now necessary to further explore the mechanisms responsible for the exercise-induced 471 
decrease in in vivo immunity and suitable nutritional countermeasures. 472 
 473 
Limitations 474 
The results for erythema responses were generally in line with the oedema responses but 475 
when comparing to the CON data of Diment et al. [20] the summed response was 476 
significantly lower in the Ex-CHO condition (~41%) but there was only a trend for lower 477 
responses in the Ex-PLA group (~32%). Importantly, however, there was no difference 478 
between the Ex-PLA and Ex-CHO groups (if anything the response was lower in the CHO 479 
group). Since the use of erythema may suffer from interference at sites of a strong response, 480 
where yellow vesicles can interfere with the erythema readings [19, 20] the oedema results of 481 
this study should be taken as the primary indication of CHS. Importantly, even if using the 482 
erythema data, the overall conclusion would remain the same, that acute CHO ingestion 483 
before, during and after prolonged exercise does not benefit in vivo immunity. 484 
 485 
We recognise a limitation of the current study is that we did not concurrently measure any of 486 
the previously reported functional in vitro markers (e.g. neutrophil function, lymphocyte 487 
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proliferation, stimulated cytokine production) for comparison with in vivo responses. 488 
However, it is well-established and consistently reported that CHO supplemention blunts 489 
many of the prolonged-exercise-induced alterations in in vitro immune measure (e.g. [4, 5, 9–490 
11]). Our current results do not suggest that  subjects’ responses were any different from 491 
those typically observed in such studies: we observed the typical exercise-induced increases 492 
of stress hormones and leukocyte trafficking which were blunted by CHO ingestion.  This 493 
study therefore supports the recent findings of Diment et al. [20] that the induction of 494 
immune memory is decreased by prolonged exercise but the circulating stress hormone 495 
responses do not appear to be responsible. This also agrees with Oliver et al. [21] who 496 
showed that reduced CHS responses after ascent to altidude were not related to the stress 497 
hormone response. The current study does support the previously reported effects of CHO 498 
supplementation on blunting of stress and leukocytosis responses to prolonged exercise (e.g. 499 
[4, 5, 9, 11]) but it does not support the use of CHO as an acute nutritional intervention of 500 
benefit to in vivo immunity.  This also seems to support the notion that in vitro measures do 501 
not sufficiently capture the whole integrated immune response and as such, are not 502 
representative of in vivo host defence.  As a result, it would be beneficial for future studies to 503 
include in vivo measures in order to test the utility of proposed nutritional countermeasures 504 
for immune impairment after prolonged exercise.  505 
 506 
We also recognise that the CHS response to DPCP is benign, and the clinical significance of 507 
the response, with specific regard to URTI in athletes, has not yet been established [20]. 508 
Nevertheless, the clinical relevance of in vivo cutaneous immune measures has been 509 
demonstrated in other contexts e.g. relationships with the progression of immunodeficiency; 510 
progression of acute to persistent diarrhoea; and URTI risk in children [14, 26–28]. In the 511 
current study, we have used the CHS response as a marker of in vivo immune function but do 512 
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acknowledge that future research must confirm the relationship between this and illness (e.g. 513 
URTI) risk in athletes.  514 
 515 
Conclusion 516 
Based on the results of this study, acute CHO ingestion before, during and after exercise does 517 
not blunt the decrease of in vivo immunity observed following 2 h of moderate exercise in the 518 
fed state (exercise commencing 3.5 h after breakfast). It remains to be determined, however, 519 
whether there would be any benefit with exercise that places a greater stress on CHO 520 
availability (e.g. longer duration and/or in the fasted state), or during periods of intensified 521 
training. However, we propose that the current design is relevant to what many athletes 522 
actually do in training and competition and would expect similar findings if repeated during 523 
regular training, althouh the effects of more chronic CHO supplementation (i.e. during 524 
regular training for weeks or months) require further investigation.  525 
  526 
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Figure legends 619 
 620 
 621 
 622 
 623 
 624 
 625 
 626 
 627 
 628 
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 630 
  631 
Figure 1. CHS response to DPCP elicitation 28 d after sensitisation: Summed increase in skin-fold 
thickness (left panel, values are mean ± SD) and full dose-series response (right panel, values are mean ± 
SEM), 48 h post elicitation.   
#note: Responses were also compared to 16 resting control (CON) subjects from Diment et al. [20] for additional 
comparison with a resting non-exercise condition (n = 16, 120 minutes of seated rest). 
* Indicates significantly different to CON (P < 0.05). There were no differences between Ex-PLA and Ex-CHO 
Figure 2. CHS response to DPCP elicitation 28 d after sensitisation: Summed increase in erythema (left 
panel, values are mean ± SD) and full dose-series response (right panel, values are mean ± SEM), 48 h 
post elicitation.   
#note: Responses were also compared to 16 resting control (CON) subjects from Diment et al. [20] for additional 
comparison with a resting non-exercise condition (n = 16, 120 minutes of seated rest). 
* Indicates significantly different to CON (P  < 0.05). There were no differences between Ex-PLA and Ex-CHO 
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Table 1. Subject demographics 
 PLA-Ex 
(n = 16) 
CHO-Ex 
(n = 16) 
t-test P value 
 
Height (m) 1.79 (0.05) 1.78 (0.05) 0.489 
 
 
Weight (kg) 
 
76.4 (10.4) 
 
76.0 (10.0) 
 
0.916 
 
 
BMI (kg·m-2) 23.8 (3.0) 24.0 (2.6) 0.827 
 
 
Age (years) 29 (8) 29 (8) 0.864 
 
Training (h) 7 (3) 6 (2) 0.721 
 
?̇?O2max  
(ml·kg-1·min-1) 
55.7 (6.1) 60.9 (5.6) 0.017 
 
Values are mean (SD)  
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Table 2. Exercise responses during main trial 
 PLA-Ex CHO-Ex t-test P value 
%Δ @ 60% ?̇?O2max 39.6 (28.7)% 38.8 (36.4)% 0.622 
 
 
Mean % ?̇?O2max 59.6 (4.9)% 58.2 (4.7)% 0.432 
 
 
HR (bpm) 140 (15) 138 (12) 0.686 
 
RPE 11 (2) 11 (2) 0.182 
Values are mean (SD)  636 
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Table 3. Leukocyte responses to exercise 
 Pre-Ex Post-Ex 1 h Post-
Ex 
ANOVA main effects 
(group; time; trial × time) 
 
Leukocyte count 
(×109.l-1)        Ex-PLA 
  Ex-CHO 
 
 
5.1 (1.2) 
5.6 (0.8) 
 
 
10.4 (2.9)  
7.1 (1.3) aa 
 
 
10.2 (2.7)  
6.2 (0.6) aa 
 
 
0.313 ; <0.001 ; <0.001 
 
Neutrophil count 
(×109.l-1)         Ex-PLA 
  Ex-CHO  
 
3.2 (1.0) 
3.2 (0.6) 
 
7.6 (2.6)  
4.7 (1.2) aa 
 
7.9 (2.1)  
4.1 (0.8) aa 
 
0.005 ; <0.001  ; <0.001   
 
Lymphocyte count 
(×109.l-1)      Ex-PLA 
  Ex-CHO  
 
1.4 (0.4)  
1.6 (0.5) 
 
1.8 (0.7) 
1.7 (0.4) 
 
1.3 (0.5)  
1.4 (0.4) 
 
0.830 ; <0.001  ; 0.037   
 
N:L ratio 
          Ex-PLA 
  Ex-CHO  
 
2.5 (1.2) 
2.2 (1.0) 
 
4.9 (2.7)  
2.9 (0.9) 
 
6.5 (2.3)  
3.2 (1.2) aa 
 
0.053 ; <0.001  ; <0.001   
 
N:L ratio: Neutrophil-to-Lymphocyte ratio. Values are mean (SD); 
Post hoc (between groups): Significantly different to Ex-PLA a (P <0.05), aa (P <0.01). Post hoc results 
for significant time effects are described in the text of results section but not shown in above table.   
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 Table 4. Glucose and stress hormone responses to exercise 
 Pre-Ex Post-Ex 1 h Post-Ex ANOVA main effects 
(group; time; trial × time) 
     
Plasma Glucose   (mmol.l-1)  
   Ex-PLA 
   Ex-CHO 
 
4.5 (0.8) 
4.2 (0.8) 
 
4.2 (0.6)  
5.9 (0.9) aa 
 
3.8 (0.9) 
5.1 (1.1) aa 
 
0.002 ; 0.007 ; <0.001 
 
Cortisol (nmol.l-1)         
   Ex-PLA 
   Ex-CHO 
 
 
367 (187) 
488 (159) 
 
431 (218)  
259 (98) a 
 
398 (175)  
269 (81) a 
 
0.263 ; 0.037 ; 0.001 
 
Adrenaline   (nmol.l-1)         
   Ex-PLA 
   Ex-CHO 
 
 
0.37 (0.27) 
0.37 (0.28) 
 
0.96 (1.26) 
0.62 (0.31) 
 
0.45 (0.44) 
0.31 (0.09) 
 
0.961 ; 0.002  ; 0.857   
     
Noradrenaline (nmol.l-1)    
   Ex-PLA 
   Ex-CHO 
 
3.15 (1.53) 
2.96 (1.14) 
 
4.71 (2.02)  
4.98 (1.19) 
 
3.30 (1.19)  
3.18 (0.77)  
0.949 ; <0.001  ; 0.701   
 
Values are mean (SD); 
Post hoc (between groups): Significantly different to Ex-PLA a (P <0.05), aa (P <0.01). Post hoc results 
for significant time effects are described in the text of results section but not shown in above table.   
